| AA | arachidonic acid |
| AIDS | acquired immunodeficiency syndrome |
| BBB | blood–brain barrier |
| CCL2 | C-C motif chemokine ligand 2 |
| CNS | central nervous system |
| CVD | cardiovascular disease |
| DAG | diacylglycerol |
| FA | fatty acid |
| HAART | highly active antiretroviral therapy |
| HAND | HIV-associated neurocognitive disorder |
| HIV-1 | human immunodeficiency virus type I |
| IP3 | inositol 1,4,5-trisphosphate |
| LDL | low-density lipoprotein |
| LPA | lysophosphatidate |
| LPC | lysophosphatidylcholine |
| Lp-PLA2 | lipoprotein-associated phospholipase A2 |
| LPS | lipopolysaccharide |
| LT | leukotriene |
| NF-kB | nuclear factor kappa-light-chain-enhancer of activated B cells |
| NO | nitric oxide |
| PAF | platelet-activating factor |
| PC | phosphatidylcholine |
| PC-PLC | phosphatidylcholine specific phospholipase C |
| PG | prostaglandin |
| PI | phosphoinositide |
| PI-PLC | phosphoinositide-specific phospholipase C |
| PL | phospholipase |
| PLA2 | phospholipase A2 |
| cPLA2 | cytosolic PLA2 |
| iPLA2 | Ca2+-insensitive phospholipase A2 |
| sPLA2 | secretory phospholipase A2 |
| ROS | reactive oxygen species |
| SIV | simian immunodeficiency virus |
| TNF | tumor necrosis factor |